Why the study?
The field of Sydenham's chorea is marked by conflicting results and controversies, with limited high-quality interventional studies to guide treatment selection.
This review outlines the pathophysiology and clinical features of Sydenham's chorea and proposes a serial treatment algorithm despite the lack of high-quality evidence.
Sydenham's chorea care integrates neuropsychiatric and rheumatic features; review leaves open optimal immunomodulatory strategies.
Sydenham's chorea is an autoimmune chorea emerging after a group A beta-hemolytic streptococcal (GABHS) infection, i.e. a rheumatic chorea with or without the presence of carditis or arthritis. The disorder, defined by the presence of chorea, is also associated with cognitive and behavioral symptoms, including emotional lability, anxiety, depressive and obsessive-compulsive symptoms. The authors review the pathophysiology, clinical characteristics, and available evidence on therapeutic strategies, the latter including the secondary prevention of GABHS infections, reduction of chorea, and immune modulation. Sydenham's chorea has been regarded as a model for pediatric autoimmune neuropsychiatric disorders, however, the field is marked by conflicting results and controversies. Regarding therapeutics, there are limited high-quality interventional studies and the selection of treatment strategy often relies on the clinician's experience. A serial treatment algorithm is presented based upon the severity of clinical presentation and response to symptomatic pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
Teixeira et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: